Genome-wide functions of PML–RARα in acute promyelocytic leukaemia

S Saeed1, C Logie1, HG Stunnenberg1 and JHA Martens*,1
1Department of Molecular Biology, Faculty of Science, Nijmegen Centre for Molecular Life Sciences, Radboud University, 6500 HB Nijmegen, The Netherlands

PML—RAR (retinoic acid receptor)α is the hallmark protein of acute promyelocytic leukaemia, a highly malignant subtype of acute myeloid leukaemia (AML) that accounts for approximately 10% of all AML cases. Recently, several studies have been set out to obtain a comprehensive genome-wide view of the molecular actions of this chimeric protein. In this review, we highlight the new insights that arose from these studies, in particular focussing on newly identified PML–RARα target genes, its interplay with RXR and deregulation of epigenetic modifications.

Keywords: PML–RARα; RXR; PU.1 (SPI1); epigenome

Acute promyelocytic leukaemia (APL) is a distinctive subtype of acute myeloid leukaemia (AML) that accounts for approximately 10% of all AML cases (Jing, 2004). The disease represents a highly malignant form of leukaemia with high bleeding tendency and a fatal course of only few weeks (Wang and Chen, 2008). The main diagnostic feature of APL is an aberrant chromosomal translocation that juxtaposes the PML gene on chromosome 15 and the RXR gene on chromosome 17 (Kakizuka et al, 1991). The resultant chimeric protein, which is found in over 95% of human APLs (Di Croce, 2005), retains the DNA-binding and ligand-binding domains of RARα and the multimerisation domain of PML. In normal cells PML is a main constituent of nuclear bodies, which are matrix-associated multiprotein-containing domains involved in various biological functions like DNA-damage response and microorganism resistance through regulation of a wide range of proteins, among which are various transcription factors (Lallemand-Breitenbach and de The, 2010). In contrast, in APL, the expression of PML–RARα disrupts the localisation of the wild-type PML from nuclear bodies to numerous micro speckles (Brown et al, 2009) and induces a maturation block at the promyelocytic level (Wang and Chen, 2008). All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are the two most important drugs in clinical use for the treatment of early-diagnosed APL. Both ATRA and ATO degrade the PML–RARα fusion protein by acting on the RARα and PML moieties, respectively. ATRA mainly degrades the protein through proteasome-mediated pathways (Zhu et al, 1999) and caspases (Nervi et al, 1998), while ATO-induced degradation is initiated through sumoylation of the PML moiety. Both treatments ultimately lead to restoration of PML nuclear bodies (Lallemand-Breitenbach et al, 2008; Zhang et al, 2010), but whether this is important for curing the disease is an open question.

Various mechanisms have been proposed for PML–RARα functioning. It has been suggested that PML–RARα can form homodimers without RXR (Minucci et al, 2000) or that it forms PML–RARα oligomers that heterodimerise with RXR (Perez et al, 1993; Jansen et al, 1995). In addition, it has been suggested that during transformation PML–RARα induces a multitude of alterations in the chromatin architecture. These alterations are achieved through the recruitment of various epigenetic-modifying factors, like histone deacetylase complexes such as SMRT (Lin et al, 1998) and N-CoR (Grignani et al, 1998), and DNA methyltransferases (Di Croce et al, 2002). In addition, recent evidence suggests co-recruitment of the histone methyltransferases SUV39H1 and polycomb repressor complexes, which dictate the epigenetic state of H3K9 (Carbone et al, 2006) and H3K27 (Villa et al, 2007), respectively. Unfortunately, most of these studies showed epigenetic alterations only around a limited set of binding regions, in most cases the RARα promoter. This was largely due to unavailability of the genome-wide PML–RARα target site repertoire. However, the recent advances in high-throughput tools have, for the first time, made it possible to look at the genome-wide actions of PML–RARα and different epigenetic marks associated with its binding. Indeed, two recent studies have provided a more global picture of PML–RARα functioning by identifying binding regions of PML–RARα, using state-of-the-art ChIP-seq and ChIP-on-chip technologies. Importantly, the new technologies even allowed extension from the commonly used model cell lines to primary APL blasts, highlighting the new opportunities that have now become available.

In this review we will focus on the various aspects of PML–RARα functioning with respect to its genome-wide binding spectrum, its interplay with RXR and its regulation of various epigenetic modifications. In addition, we will discuss some of the newly identified target genes and target pathways of PML–RARα.

ALTERED RAR SIGNALLING IN APL CELLS

All-trans retinoic acid belongs to the group of vitamin A-derived substances and binds three major RARs, RARα, β and γ. The full execution of the ATRA signalling pathway operates by inductibly
controlling the expression of the genes that have a direct repeat with spacing 2 or 5 (DR2 or DR5) in their promoter (de The et al., 1991). Retinoind signalling has a key role in various developmental and differentiation processes. According to the classical model, RAR and RXR, another nuclear receptor, heterodimerise under non-ATRA conditions, recruit co-repressors and silence target gene expression. In this model, RAR binding to ATRA results in a conformational change in the RXR–RAR heterodimer, allowing recruitment of gene-activating complexes and resultant gene expression. In APL, PML–RARα is thought to behave functionally as an altered RARα that has lost the potential to respond to fluctuations in physiological ATRA concentration, and as a result acts as a constitutive transcriptional repressor for DR2- or DR5-containing genes. Strikingly, recent studies that analysed the genome-wide binding of PML–RARα binding sites not only identified DR2 and DR5 elements as the primary PML–RARα response elements, but also regions containing DR1, DR3 and DR4 motifs and even more atypical DR motifs with various spacing and orientation were detected (Martens et al., 2010), thereby extending in vivo previous in vitro data (Kamashev et al., 2004). This rather diverse repertoire of response elements present at the PML–RARα binding sites underscores the idea of a gain of DNA-binding capacity as an essential feature of PML–RARα-mediated transformation. In addition to this extended binding potential, global binding data of PML–RARα using ChIP-seq revealed PML–RARα binding to the RARα, RARβ and RARγ genes itself (Table 1), suggesting that expression of these proteins is directly regulated by PML–RARα (Martens et al., 2010). All these data suggest that PML–RARα affects ATRA signalling at multiple levels: first by regulating expression of the genes involved in transmitting the ATRA signals, second through an altered regulation of classical DR2- and DR5-containing RAR/RXR target genes and third through an extension of the (PML-)RAR binding potential towards more degenerate DR-containing regulatory sites.

### Table 1

| Gene name | Chromosome | Start PML–RARα peak | End PML–RARα peak | Peak location |
|-----------|------------|---------------------|-------------------|--------------|
| GFI1      | chr1       | 92714254            | 92714749          | Gene body    |
| RUNX1     | chr21      | 35159419            | 35160205          | Gene body    |
| RUNX3     | chr1       | 25221279            | 25222122          | Distal       |
| JUND      | chr19      | 18263175            | 18264260          | Upstream far |
| JUNB      | chr19      | 12760408            | 12760879          | Upstream near|
| SETDB1    | chr1       | 14916528            | 14916561          | Upstream near|
| DNMT3A    | chr2       | 25377769            | 25378201          | Gene body    |
| JMJ1D/2   | chr2       | 86521292            | 86521853          | Upstream near|
| HDAC4     | chr2       | 239913436           | 239913935         | Gene body    |
| HDAC9     | chr17      | 18323574            | 18323895          | Distal       |
| PRMT3     | chr11      | 20365226            | 20365660          | Gene body    |
| SETDB2    | chr12      | 122434062           | 122434727         | Gene body    |
| PRMT7     | chr16      | 66947562            | 66948286          | Gene body    |
| JMJ3D     | chr17      | 7682360             | 7683526           | Upstream near|
| DOTIL     | chr19      | 2119325             | 2119752           | Gene body    |
| PU.1 (SPI1) | chr11   | 47337456            | 47338471          | Gene body    |
| RARβ      | chr17      | 35762620            | 35763210          | Gene body    |
| RARβ      | chr3       | 25444370            | 25449450          | Upstream near|
| RARG      | chr12      | 51897334            | 51897732          | Gene body    |

Abbreviation: RAR, retinoic acid receptor.

### PML–RARα CROSS TALKS WITH OTHER TRANSCRIPTION FACTORS

Apart from interacting with RXR, PML–RARα has been suggested to interact with many other proteins. Amongst these are various key haematopoietic regulatory transcription factors such as GATA-2, PU.1 and AP-1 factors. PML–RARα is proposed to be involved in inhibition of AP-1 transcriptional activity in an ATRA-dependent manner. This is illustrated by the observation that PML–RARα interacts with c-Jun and c-Fos and that the repressive effect on AP1 binding sites, thereby reversing the ATRA treatment (Doucas et al., 1993). There is also evidence of a physical association of GATA2 with PML–RARα. This interaction is suggested to result in enhanced GATA2-dependent transactivation capacity (Tsuzuki et al., 2000). In line with these two studies is the observation that PML–RARα binding was detected not only near several of these factors such as JUNB and JUND, but also near GATA2 (Table 1) (Martens et al., 2010), suggesting that these factors are affected both at the level of their expression and in their targeting capacities. In addition, we observed PML–RARα binding at several other key regulators of haematopoiesis such as PU.1 (see below) RUNX1, RUNX3 and GFI1 (Table 1). This extends the observation that PML–RARα regulates the classical targets of the retinoic acid signalling pathway to many other key players in haematopoiesis.

### BINDING OF PML–RARα WITH PU.1

PU.1 is a protein that is essential for the haematopoietic differentiation process. PU.1 mutants lead to embryonic lethality at a late gestational stage (Scott et al., 1994). Mice that have homozygous disruption of the DNA-binding domain of PU.1 have severe septicemia and die within 48 h of their birth (McKercher et al., 1996). In addition, PU.1 has been shown to be essential for reprogramming B-cells into the myeloid lineage (Xie et al., 2004). Already in 2006 it was proposed that PML–RARα interacts with PU.1 and PU.1 is the action of RARα is suppressed upon expression of PML–RARα, thereby resulting in a differentiation block (Mueller et al., 2006). In these studies, ATRA treatment and the ensuing PML–RARα degradation resulted in restoration of PU.1 expression and a release of the differentiation block. These studies already hinted at the molecular interplay of PU.1 with PML–RARα. A recent study based on genome-wide binding of PML–RARα using ChIP-seq revealed a PML–RARα inducible cell model, further shedding light on the PU.1 and PML–RARα interaction (Wang et al., 2010). In this study, more than 84% of the detected PU.1 motifs were found in the close vicinity of variably spaced direct repeats (DRs). Further functional analysis suggested that the binding of PML–RARα to the regions containing both PU.1 and DRs is a prerequisite for subsequent repression of chromatin at

(Minucci et al., 2000), several studies support a role of RXR in the PML–RARα transformation process. RXR was already described as part of the PML–RARα oncogenic complex in in vitro settings (Kamashev et al., 2004). In addition, recent studies highlighted the importance of RXR in PML–RARα-mediated transcriptional repression (Zegis et al., 2007; Zhu et al., 2007). These studies showed that impaired RXR binding by PML–RARα mutants impairs APL development in transgenic mice while still retaining the transforming potential in vitro. Furthermore, they showed that silencing of RXR by shRNA suppresses the RARα fusion-mediated transformation in vitro. These studies were corroborated and extended by the identification of genome-wide association of RXR with PML–RARα (Martens et al., 2010). For 99% of PML–RARα binding sites, association of RXR was noted. Together, these factors such as the importance of RXR in the PML–RARα-mediated transformation process. It may therefore be interesting to also test RXR antagonists (Altucci et al., 2007) in this subtype of AML.
PU.1 targeted regions. In addition to these observations, the PU.1 gene was found to be a direct target of PML–RARα (Martens et al., 2010). Interestingly, binding of PML–RARα was not detected at the promoter regions but rather in the third intron of the PU.1 gene (Table 1). As this intronic region has also been reported to contain the transcription start site of an antisense transcript that acts as a putative negative regulator of PU.1 expression (Ebralidze et al., 2008), these results identify for the first time PML–RARα-mediated regulation of a non-coding transcript.

**PML–RARα AFFECTS THE EPGENOME**

Multiple studies have suggested that central to oncogenic transformation in APLs is the PML–RARα-induced mis-targeting of the epigenetic machinery, thereby causing a perturbation of the normal epigenetic landscape. Genome-wide binding analysis of PML–RARα (Martens et al., 2010) revealed that various enzymes that can set different chromatin modifications are targeted by PML–RARα, including JMJD3 (H3K27me3 demethylation), SETDB1, JMJD1A (H3K9 modifiers), deacetylases like HDAC4 and 9, and genes involved in DNA methylation, such as DNMT3A (Table 1). These findings suggested that PML–RARα expression has the potential to confer a genome-wide alteration in epigenetic make-up. In addition to the direct transcriptional regulation of epigenetic enzymes, different labs have explored the epigenetic marks that are recruited by PML–RARα itself. Histone marks such as H3K27me3 and H3K9me3, as well as DNA methylation, have been proposed to be positively correlated with PML–RARα binding, whereas H3 acetylation was associated with loss of PML–RAR binding. The dynamic changes of DNA methylation, H3K9me3 and H3K27me3 functioning are suggested to be regulated by DNA methyltransferases, histone methyltransferase (SU39H1) and polycomb repressive complex 2 (PRC2), respectively, and all these proteins have been suggested to interact with the PML–RARα complex in several independent studies (Di Croce et al., 2002; Carbone et al., 2006; Villa et al., 2007). H3 acetylation was the first chromatin modification associated with PML–RARα binding and is a mark that is negatively correlated with PML–RARα binding. Mechanistically, this is thought to be achieved through PML–RARα-mediated recruitment of HDACs (Grignani et al., 1998; Lin et al., 1998). Indeed, in vivo studies could show that there is a significant increase of H3 acetylation upon ATRA-mediated degradation of PML–RARα at the RARβ promoter (Villa et al., 2007). Still, the limiting factor to this observation and also other studies that investigated epigenetic marks was the number of PML–RARα binding regions addressed and, therefore, the generality of the proposed mechanisms. The recent genome-wide interrogation of APL (Martens et al., 2010) allowed for the first time expansion to all binding regions of PML–RARα. This showed that there was a significant regulation of local H3 acetylation at more than 80% of the PML–RARα binding regions, illustrated by the observation that H3 acetylation levels at these sites were significantly elevated upon ATRA-induced PML–RARα degradation. In contrast, changes in other epigenetic marks such as H3K9me3, H3K27me3 and DNA methylation could not be generalised towards all PML–RARα binding sites, as the vast majority of sites did not show a significant change after ATRA treatment. These findings are
of significant worth, as they point out the importance of the role of histone deacetylases in maintenance of repressed chromatin architecture at PML–RARα binding sites. This sanctions the idea of making HDACs direct targets for therapeutic treatment of APL by using specific inhibitors for these proteins.

OUTLOOK

In this review, we focused on two recent studies that describe a global analysis of PML–RARα (Martens et al, 2010; Wang et al, 2010). Both studies have shown nearly 3000 genome-wide direct targets of PML–RARα by using high-throughput sequencing and array-based technologies, and provided a significant step forward in understanding PML–RARα-mediated leukaemogenesis. Although these studies used independent platforms, several common conclusions were drawn (Figure 1). One of these is the extended binding repertoire of PML–RARα in comparison with the non-fused RAR. Indeed, direct, inverted and everted repeats with various spacing and orientation were detected in vivo for PML–RARα binding sites in comparison with the classical DR2 and DR5 motifs that are the hallmarks of heterodimerised RARα/RRX binding regions. In addition to the DR motifs, the discovery of DNA motifs for PU.1 resulted in the finding that PU.1 colocalises with PML–RARα.

The above studies highlighted the fact that PML–RARα not only binds to the promoter regions of target genes but also has a rather diverse repertoire of binding sites. This complex binding spectrum suggests a potential influence on long-range chromosomal interactions by PML–RARα. The wide-ranging molecular alterations induced by PML–RARα are further illustrated by the fact that PML–RARα regulates several key regulators of normal haematopoiesis, such as PU.1, GATA-2, RUNX1 and many others, as well as different pathways such as RAR signalling. In addition, exploration of the epigenetic environment of the APL genome before and after ATRA treatment gave significant insights into PML–RARα regulation. An inverse correlation of PML–RARα with H3 acetylation was revealed at the PML–RARα binding sites themselves, while the genome-wide epigenetic environment was also significantly remodelled. Still, more in-depth functional studies are needed to provide an answer as to whether histone H3 acetylation levels or other epigenetic markings are crucial in the PML–RARα-induced transformation process. Nevertheless, current data already hint at potential drug targets such as acetyltransferases and deacetylases, as well as RXR for treatment of APL.

Despite the wealth of important insights on PML–RARα functioning provided by the above studies, the question still remains as to what the crucial determinant for PML–RARα binding to a particular region actually is. Is it the underlying motif, interaction with other transcription factors, the chromatin accessibility, or a combination of all three? In order to obtain a better comprehension of normal haematopoiesis and leukaemia, it will be important to address these crucial questions. At the same time, deeper insight is required into the molecular behaviour of other oncofusion proteins that harbour functional properties similar to PML–RARα’s such as AML1-ETO, which is the result of the t(8;21) chromosomal translocation, or the inv(16) translocation that gives rise to the CBFB/MYH11 oncofusion protein (Martens and Stunnenberg, 2010). A comparative analysis of the molecular actions of several oncofusion proteins is expected to uncover some of the more general mechanisms that are used by these proteins to transform cells.

ACKNOWLEDGEMENTS

This work was supported by the European Union LSHC-CT-2005-518417 ‘Epitron’ and the Dutch Cancer Foundation (KWF KUN 2009-4527) and Higher Education Commission of Pakistan.

REFERENCES

Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H (2007) RAR and RXX modulation in cancer and metabolic disease. Nat Rev Drug Discov 6: 793 – 810

Brown NJ, Ramalho M, Pedersen EW, Moravcsik E, Solomon E, Grimwade D (2009) PML nuclear bodies in the pathogenesis of acute promyelocytic leukaemia: active players or innocent bystanders? Front Biosci 14: 1684 – 1707

Carbone R, Botrugno OA, Ronzoni S, Inaniga A, Di Croce L, Pelicci PG, Minucci S (2006) Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukaemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol 26: 1288 – 1296

de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A (1991) The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukaemia encodes a functionally altered RAR. Cell 66: 675 – 684

Di Croce L (2005) Chromatin modifying activity of leukaemia associated fusion proteins. Hum Mol Genet 14 Spec No 1: R77 – R84

Ebralidze AK, Guibal FC, Steidl U, Zhang P, Lee S, Bartholdy B, Jorda MA, Petkova V, Rosenbauer F, Huang G, Gujarath T, Klupp J, O’Brien KB, Will B, Hoogkamp M, Borden KL, Bonifac C, Tenen DG (2009) PUL1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev 22: 2085 – 2092

Grignani F, De Mattesi S, Nervi C, Tomassoni L, Gelmetti V, Cioc M, Fanelli M, Rathard M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815 – 818

Jansen JH, Mahfoudi A, Rambaud S, Lavau C, Walsh W, Dejean A (1995) Multimeric complexes of the PML-retinoic acid receptor alpha fusion protein in acute promyelocytic leukaemia cells and interference with retinoid and peroxisome-proliferator signaling pathways. Proc Natl Acad Sci USA 92: 7401 – 7405

Jing Y (2004) The PML-RARα fusion protein and targeted therapy for acute promyelocytic leukaemia. Leuk Lymphoma 45: 639 – 648

Kakizuka A, Miller JR WH, Umesono K, Barrett JR RP, Frankel SR, Murty VV, Dmitrovsky E, Evans RM (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukaemia fuses RAR alpha with a novel putative transcription factor. PML Cell 66: 663 – 674

Kamashev D, Vitoux D, De Th E (2004) PML-RARα-RXR oligomers mediate retinoid and retinoid/cAMP cross-talk in acute promyelocytic leukaemia cell differentiation. J Exp Med 199: 1163 – 1174

Lallemand-Breitenbach V, de Th E (2010) PML nuclear bodies. Cold Spring Harb Perspect Biol 2: a000661

Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, De Th E (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-activated RNF4 ubiquitinated-mediated pathway. Nat Cell Biol 10: 547 – 555

Lin RJ, Nagy L, Ionou S, Shao W, Miller JR WH, Evans RM (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391: 811 – 814

Martens JH, Brinkman AB, Simmer F, Francois KJ, Nebiobaso A, Ferrara F, Altucci L, Stunnenberg HG (2010) PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukaemia. Cancer Cell 17: 173 – 185

Martens JH, Stunnenberg HG (2010) The molecular signature of oncofusion proteins in acute myeloid leukaemia. FEBS Lett 584: 2662 – 2669
